ORLANDO, FL / ACCESSWIRE / May 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today it has booked nearly a quarter of a million dollars in new in contract manufacturing orders through its wholly-owned subsidiary Pocono Pharma, extending its current run of record-breaking revenue. The reported amount of the orders, which is just over $234,000, exceeds the …
ORLANDO, Fla., April 29, 2022 /PRNewswire/ — Nutriband Inc. (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2022. Key Highlights: Generated record revenue of $1.4 million, up 56% over the prior fiscal year Completed uplisting to Nasdaq Capital Market in October 2021 and concurrent offering that raised total gross …
Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4M Read More »
ORLANDO, Fla., Dec. 15, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it signed an exclusive license agreement with RAMBAM Med Tech Ltd, a Division of the RAMBAM Hospital, the largest medical center in Northern Israel, for its Closed System Transfer Device designed to liquify drugs for patients who cannot swallow solids. The Closed System Transfer Device …
ORLANDO, Fla., Dec. 16, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, is pleased to announce that it has reported record 2020 revenues for three and nine months ended October 31, 2020. In the third quarter of 2020, the Company recorded $391,797 in revenues as compared to $82,567 for the same period last year; for the nine months ended October 31, 2020 the Company recorded $595,611 in …
ORLANDO, Fla., Dec. 10, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the “Company”) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the ‘Abuse and Misuse Deterrent Transdermal Systems’ patent application filed by its clinical subsidiary 4P Therapeutics. The patent underpins 4p Therapeutics’ abuse deterrent fentanyl transdermal system, AVERSA, which uses Taste aversion …
ORLANDO, Fla., Sept. 15, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), announced that it has agreed terms with Irish based Oran Textiles Ltd. for the US and Korean distribution rights for Oran Textiles V-block coated facemasks. The masks, are a marriage of Italian based Cifra’s Warpmask technology with HEIQ V-Block (Viroblock) technology. HeiQ’s V-Block technology shown strong antimicrobial efficacy …
ORLANDO, Fla., Sept. 2, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it has completed the acquisition of Pocono Coated Product’s Transdermal and Health product manufacturing business effective August 31, 2020. Pocono Coated Products was established in 2004 with a focus on the manufacturing of custom coated products and providing manufacturing and development services for 3rd party …
ORLANDO, Fla., July 22, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation has announced that the application for its ‘AVERSA’ Trademark in relation to its abuse deterrent technology and lead product candidate has passed the examination and third party opposition phase and the company expects to receive a notice of allowance in due time. Previously named Defent, AVERSA™ …
Nutriband’s AVERSA Trademark Application Receives No Opposition Read More »
ORLANDO, Fla., July 16, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada Corporation, announced that it has agreed terms for the acquisition of Pocono Coated Product’s Transdermal and Health product manufacturing Business. The acquisition is another step in our expansion plans to strengthen the company, following our acquisition of 4P Therapeutics. Pocono is set to become the manufacturing …
Nutriband Inc. and Pocono Coated Products Agree Terms on Acquisition Read More »
ORLANDO, Fla., March 18, 2020 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the “Company”) has received a notice of grant from patent offices in Australia and Russia and a notice of allowance from Mexico’s patent office for the ‘Abuse and Misuse Deterrent Transdermal Systems’ patent application filed by its clinical subsidiary 4P Therapeutics The patent underpins 4P Therapeutics’ abuse deterrent fentanyl transdermal system, which uses taste aversion …
Nutriband Inc. Receives Patent Protection from Australia, Russia and Mexico Read More »